Characteristics of different pathogenic bacterial infections and their effects on prognosis in adult patients with bronchiectasis

Niu,Yueying; Lian,Xue; Li,Xiaosi; Ge,Xiang; Wang,Haiqin

doi:10.3892/etm.2024.12745

Characteristics of different pathogenic bacterial infections and their effects on prognosis in adult patients with bronchiectasis

Authors:
- Yueying Niu
- Xue Lian
- Xiaosi Li
- Xiang Ge
- Haiqin Wang
View Affiliations

Affiliations: Department of Respiratory Medicine, The Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang 314000, P.R. China, Clinical Laboratory, The Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang 314000, P.R. China
Published online on: October 14, 2024 https://doi.org/10.3892/etm.2024.12745
Article Number: 455
Copyright: © Niu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to analyse the types of pathogens infecting adults with bronchiectasis and the effects of different pathogens on the number of acute exacerbations and the length of hospitalization for 1 year in patients with severe bronchiectasis. A total of 522 patients with bronchiectasis admitted to the Department of Respiratory and Critical Care Medicine at the Second Hospital of Jiaxing (Zhejiang, China) between January 2019 and December 2022 were retrospectively analysed. The patients were divided into a mild to moderate group and a severe group according to the bronchiectasis severity index criteria. The basic and clinical information of all the patients was collected. The patients were followed up for 1 year after the day when the sputum or alveolar lavage fluid samples tested positive for pathogens. The follow‑up information included the exacerbation of cough symptoms, the number of hospitalizations and the number of days of antibiotic use in patients with bronchiectasis. A total of 522 patients with bronchiectasis were positive for pathogens, including 192 patients with Pseudomonas aeruginosa (P. aeruginosa; 36.8%), 60 patients with Klebsiella pneumoniae (K. pneumoniae; 11.5%), 48 patients with mixed pathogens (≥2 pathogens at the same time; 9.2%), 36 patients with Staphylococcus aureus (6.9%), 33 patients with Aspergillus fumigatus (6.3%), 30 patients with Haemophilus influenzae (5.7%), 15 patients with Acinetobacter baumannii (A. baumannii; 2.9%) and 108 patients with other pathogens (20.7%). Compared with patients with mild to moderate bronchiectasis, patients with severe bronchiectasis were more likely to have P. aeruginosa but less likely to have K. pneumoniae and other pathogens. The length of hospitalization and duration of antibiotic use in the severe group of patients with bronchiectasis caused by P. aeruginosa, A. fumigatus, or A. baumannii were significantly longer than those in the mild to moderate group. During the 1‑year follow‑up, the number of acute exacerbations and hospitalizations of patients with severe bronchiectasis caused by A. baumannii and P. aeruginosa were significantly greater than those of patients with severe bronchiectasis caused by other pathogens. According to logistic regression analysis, A. baumannii and P. aeruginosa were independent risk factors for acute exacerbation of severe bronchiectasis in the following year. In patients with severe bronchiectasis, the pathogens A. baumannii, P. aeruginosa and A. fumigatus were independent risk factors for future acute exacerbations and increased risk of hospitalization.

View Figures

View References

1	Shteinberg M, Flume PA and Chalmers JD: Is bronchiectasis really a disease? Eur Respir Rev. 29(190051)2020.PubMed/NCBI View Article : Google Scholar
2	King P, Holdsworth S, Freezer N and Holmes P: Bronchiectasis. Intern Med J. 36:729–737. 2006.PubMed/NCBI View Article : Google Scholar
3	King PT, Holdsworth SR, Freezer NJ, Villanueva E and Holmes PW: Characterisation of the onset and presenting clinical features of adult bronchiectasis. Respir Med. 100:2183–2189. 2006.PubMed/NCBI View Article : Google Scholar
4	Polverino E, Dimakou K, Hurst J, Martinez-Garcia MA, Miravitlles M, Paggiaro P, Shteinberg M, Aliberti S and Chalmers JD: The overlap between bronchiectasis and chronic airway diseases: State of the art and future directions. Eur Respir J. 52(1800328)2018.PubMed/NCBI View Article : Google Scholar
5	Mac Aogáin M, Xaverius Ivan F, Jaggi TK, Richardson H, Shoemark A, Narayana JK, Dicker AJ, Koh MS, Lee KCH, Thun How O, et al: Airway ‘resistotypes’ and clinical outcomes in bronchiectasis. Am J Respir Crit Care Med. 210:47–62. 2024.PubMed/NCBI View Article : Google Scholar
6	Berra G, Chappuis-Gisin É, Soccal PM and Plojoux J: Inhaled antibiotics for the management of non cystic fibrosis bronchiectasis. Rev Med Suisse. 13:2001–2004. 2017.PubMed/NCBI(In French).
7	Chalmers JD, Chang AB, Chotirmall SH, Dhar R and McShane PJ: Bronchiectasis. Nat Rev Dis Primers. 4(45)2018.PubMed/NCBI View Article : Google Scholar
8	Zhang XX, He JH, Pan CX, He ZF, Li HM, Lin ZH, Zhang XF, Cen LJ, Zhang RL, Shi MX and Guan WJ: Bacteria and viruses and clinical outcomes of asthma-bronchiectasis overlap syndrome: A cohort study. Clin Transl Allergy. 14(e12331)2024.PubMed/NCBI View Article : Google Scholar
9	Yang SH, Song MJ, Kim YW, Kwon BS, Lim SY, Lee YJ, Park JS, Cho YJ, Lee JH, Lee CT and Kim HJ: Understanding the effects of Haemophilus influenzae colonization on bronchiectasis: A retrospective cohort study. BMC Pulm Med. 24(7)2024.PubMed/NCBI View Article : Google Scholar
10	Loong SK, Liam CK, Karunakaran R, Tan KK, Mahfodz NH and AbuBakar S: Non-classical Bordetella sp. (closely related to Bordetella hinzii and Bordetella pseudohinzii) lower respiratory tract infection in a patient with extensive bronchiectasis: A case report. J Int Med Res. 52(3000605231214464)2024.PubMed/NCBI View Article : Google Scholar
11	McShane PJ: Investigation and management of bronchiectasis in nontuberculous mycobacterial pulmonary disease. Clin Chest Med. 44:731–742. 2023.PubMed/NCBI View Article : Google Scholar
12	Chagas MDS, Trindade Dos Santos M, Argollo de Menezes M and da Silva FAB: Boolean model of the gene regulatory network of Pseudomonas aeruginosa CCBH4851. Front Microbiol. 14(1274740)2023.PubMed/NCBI View Article : Google Scholar
13	Bronchiectasis Expert Consensus Writing Group; Pulmonary Infection Assembly, Chinese Thoracic Society. Expert consensus on the diagnosis and treatment of adult bronchiectasis in China. Zhonghua Jie He He Hu Xi Za Zhi. 44:311–321. 2021.PubMed/NCBI View Article : Google Scholar : (In Chinese).
14	Costa JC, Machado JN, Ferreira C, Gama J and Rodrigues C: The bronchiectasis severity index and FACED score for assessment of the severity of bronchiectasis. Pulmonology. (S2173-5115(17)30154-9)(2018): (Epub ahead of print).
15	Yang B, Kim BG, Han K, Jung JH, Kim JH, Park DW, Kim SH, Kim EG, Sohn JW, Yoon HJ, et al: Systemic sclerosis and risk of bronchiectasis: A nationwide longitudinal cohort study. Arthritis Res Ther. 25(209)2023.PubMed/NCBI View Article : Google Scholar
16	Jayaram L, King PT, Hunt J, Lim M, Park C, Hu E, Dousha L, Ha P, Bartlett JB, Southcott AM, et al: Evaluation of high dose N-acetylcysteine on airway inflammation and quality of life outcomes in adults with bronchiectasis: A randomised placebo-controlled pilot study. Pulm Pharmacol Ther. 84(102283)2024.PubMed/NCBI View Article : Google Scholar
17	Chen W, Ran S, Li C, Li Z, Wei N, Li J and Li N: Elevated eosinophil counts in acute exacerbations of bronchiectasis: Unveiling a distinct clinical phenotype. Lung. 202:53–61. 2024.PubMed/NCBI View Article : Google Scholar
18	Yong VFL, Soh MM, Jaggi TK, Mac Aogáin M and Chotirmall SH: The microbial endocrinology of Pseudomonas aeruginosa: Inflammatory and immune perspectives. Arch Immunol Ther Exp (Warsz). 66:329–339. 2018.PubMed/NCBI View Article : Google Scholar
19	Shi LH, Cheng F, Gao BR, et al: Analysis of clinical characteristics of 207 inpatients with bronchiectasis in Hainan Province. Int J Respir. 43:595–603. 2023.
20	Wang R, Ding S, Lei C, Yang D and Luo H: The contribution of Pseudomonas aeruginosa infection to clinical outcomes in bronchiectasis: A prospective cohort study. Ann Med. 53:459–469. 2021.PubMed/NCBI View Article : Google Scholar
21	Finney LJ, Ritchie A, Pollard E, Johnston SL and Mallia P: Lower airway colonization and inflammatory response in COPD: A focus on Haemophilus influenzae. Int J Chron Obstruct Pulmon Dis. 9:1119–1132. 2014.PubMed/NCBI View Article : Google Scholar
22	Duff RM, Simmonds NJ, Davies JC, Wilson R, Alton EW, Pantelidis P, Cox MJ, Cookson WO, Bilton D and Moffatt MF: A molecular comparison of microbial communities in bronchiectasis and cystic fibrosis. Eur Respir J. 41:991–993. 2013.PubMed/NCBI View Article : Google Scholar
23	Miao XY, Ji XB, Lu HW, Yang JW and Xu JF: Distribution of major pathogens from sputum and bronchoalveolar lavage fluid in patients with noncystic fibrosis bronchiectasis: A systematic review. Chin Med J (Engl). 128:2792–2797. 2015.PubMed/NCBI View Article : Google Scholar
24	Sabat AJ, Pantano D, Akkerboom V, Bathoorn E and Friedrich AW: Pseudomonas aeruginosa and Staphylococcus aureus virulence factors as biomarkers of infection. Biol Chem. 402:1565–1573. 2021.PubMed/NCBI View Article : Google Scholar
25	Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, Murris M, Cantón R, Torres A, Dimakou K, et al: European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 50(1700629)2017.PubMed/NCBI View Article : Google Scholar
26	Chang AB, Bell SC, Torzillo PJ, King PT, Maguire GP, Byrnes CA, Holland AE, O'Mara P and Grimwood K: extended voting group. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand Thoracic Society of Australia and New Zealand guidelines. Med J Aust. 202:21–23. 2015.PubMed/NCBI View Article : Google Scholar
27	Pasteur MC, Bilton D and Hill AT: British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 65 (Suppl 1):i1–i58. 2010.PubMed/NCBI View Article : Google Scholar
28	Alavi Foumani A, Jafari A, Tangestani Nejad A, Jafarinejhad A, Ziyapour S, Keivanlou MH and Afzalipour M: Effects of probiotics on clinical manifestations of bronchiectasis: A randomized, triple blinded, placebo-controlled clinical trial. Tanaffos. 22:221–229. 2023.PubMed/NCBI
29	Morrow LE, Kollef MH and Casale TB: Probiotic prophylaxis of ventilator-associated pneumonia: A blinded, randomized, controlled trial. Am J Respir Crit Care Med. 182:1058–1064. 2010.PubMed/NCBI View Article : Google Scholar
30	Sarshar M, Behzadi P, Scribano D, Palamara AT and Ambrosi C: Acinetobacter baumannii: An ancient commensal with weapons of a pathogen. Pathogens. 10(387)2021.PubMed/NCBI View Article : Google Scholar
31	Yao Y, Chen Q and Zhou H: Virulence factors and pathogenicity mechanisms of Acinetobacter baumannii in respiratory infectious diseases. Antibiotics (Basel). 12(1749)2023.PubMed/NCBI View Article : Google Scholar